Shots:

• The P- III MERLIN study involves assessing the efficacy & safety of Beovu (6 mg- q4w) vs aflibercept (2 mg- q4w) following the loading phase in patients with wet AMD who have persistent retinal fluid despite anti-VEGF therapy
• Results: met its 1EPs i.e. non-inferiority in mean change in BCVA from baseline and superiority on 2EPs @ 1 yrs. Beovu (6mg- q4w) was associated with higher rates of IOI (9.3% vs 4.5%) which includes RV (0.8% vs 0.0%) & RO (2.0% vs 0.0%)- overall rate of vision (4.8% vs 1.7%)
• Novartis has decided on early termination of the RAPTOR & RAVEN studies- which assessed the efficacy & safety of Beovu in RVO- and included 6 initial monthly injections

  Ref: Novartis | Image: Novartis